EN DE

Jd Health International Inc (6618) Fair Value & Analysis

Healthcare · HK · Market cap HK$109B (≈ $13.9B) · ISIN KYG5074A1004

What is Jd Health International Inc really worth?

JH Jd Health International Inc 6618 · HK
PriceHK$37.06
Fair ValueHK$33.31
Upside−10.1%
Quality72/100

A solid business, but trading 11% above our fair value of HK$33.31.

Watch Jd Health International Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +30.5 %/yr)
✓Low debt · generates free cash flow
✓Ranks above peers (9/13)

Risks

!Thin margins · 7.3% net margin
!Narrow moat 34/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 20 out of 100
Evidence: Medium Range HK$25.38 – HK$39.19

Fair value as of: Aug 13, 2026

From 24 valuation models · updated 22 days ago

Fair value updated Aug 13, 2026, revised from HK$33.28 to HK$33.31 (+0.1%) since Aug 6, 2026. Share price −5.8% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits in the upper half of our model range, so the margin of safety is thin.
  • Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Price vs Fair Value (5 years)

HK$125.60 HK$19.82 Fair Value HK$33.31 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$19.82 – HK$125.60 · fair‑value band HK$25.38 – HK$39.19 · the HK$37.06 price screens above the HK$33.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Jd Health International Inc (6618) currently trades at HK$37.06, while our model-based Fair Value estimate is HK$33.31, implying the stock looks roughly 11.3% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$70.00 per share, and 15 of the 24 models we run sit above the HK$37.06 price. Bear case: the Asset-Based group reads lowest at HK$12.62, and 9 of the 24 models stay below the price. Evidence for this calculation is medium.

Over the trailing twelve months, Jd Health International Inc generated revenue of HK$73.4B at a net margin of 7.3%. Revenue grew 28.0% year over year. It earns a return on equity of 9.3%. The balance sheet holds a net cash position of HK$31.2B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$25.38 (bear case) to HK$39.19 (bull case); at HK$37.06, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 48% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at −10%, 6618 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$0.5481 per share, which is 1.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$61.43 HK$90.94 HK$184.91 76
Growth DCF HK$58.37 HK$106.03 HK$184.14 76
5Y EBITDA Exit HK$34.19 HK$47.07 HK$72.09 75
All 24 models by family
DCF Models
FCF DCF HK$61.43 HK$90.94 HK$184.91 76
Owner Earnings HK$37.08 HK$71.65 HK$144.24 72
5Y Revenue Exit HK$32.82 HK$44.29 HK$67.87 72
5Y EBITDA Exit HK$34.19 HK$47.07 HK$72.09 75
5Y P/E Exit HK$45.05 HK$83.19 HK$134.28 69
10Y Revenue Exit HK$41.03 HK$66.03 HK$78.12 68
10Y EBITDA Exit HK$42.52 HK$68.98 HK$110.77 67
10Y P/E Exit HK$50.45 HK$92.36 HK$159.22 61
Earnings-Based
Graham-Dodd HK$11.46 HK$79.91 HK$112.14 63
Lynch FV HK$35.89 HK$51.28 HK$66.66 61
PEG = 1.0 HK$35.89 HK$51.28 HK$66.66 57
EPV HK$19.33 HK$20.89 HK$22.26 74
Multiples
P/E Multiple HK$27.80 HK$37.07 HK$46.34 63
P/S Multiple HK$21.48 HK$28.65 HK$35.81 58
P/B Multiple HK$21.48 HK$28.65 HK$35.81 55
EV/EBIT HK$25.15 HK$30.21 HK$35.27 66
EV/EBITDA HK$23.39 HK$27.87 HK$32.34 67
EV/Revenue HK$20.80 HK$25.45 HK$30.09 54
Asset-Based
NCAV (Graham) HK$9.42 HK$12.62 HK$18.84 54
Growth DCF
Growth DCF HK$58.37 HK$106.03 HK$184.14 76
Rev-Margin DCF HK$34.15 HK$49.33 HK$79.95 71
Economic Profit
Residual Income HK$16.10 HK$17.57 HK$24.31 71
ROIC Compounder HK$20.04 HK$24.21 HK$28.40 72
Growth Earnings
Growth-Adj P/E HK$49.00 HK$70.00 HK$91.00 67

Widest divergence: Growth Earnings (HK$70.00) versus Asset-Based (HK$12.62). Highest evidence: FCF DCF (76).

Notify me when 6618 reaches fair value

Put 6618 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 17.6 as of Jul 2, 2026
P/S ratio 1.29 P/E × margin
EPS (TTM) HK$0.8100 price ÷ EPS = P/E 17.6
Net margin 7.3% FY2025
Return on equity 9.3% TTM
Return on assets (EBIT) 0.8% avg 5y
More key figures
Profitability
Operating margin 4.4% TTM
Growth
Revenue (TTM) HK$73.4B TTM
Revenue growth (YoY) +28.0% 3y avg +16.3%
EPS growth (YoY) +29.8%
Balance sheet & cash flow
Free cash flow HK$9.8B FY2025
Net cash HK$31.2B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 72/100

Of which business quality 74 · Market factors (momentum, volatility) 22

Profitability 47
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 66
Disciplined investing over empire-building
Low Volatility 44
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 73
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China.

Full company description

JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; and smart healthcare and digital health solutions. In addition, it provides online marketing services to advertisers; and online shopping and hospital services. Further, the company offers smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device set-up and support services, including blood glucose meters and oxygen generators; and rapid testing products. Additionally, it provides traditional Chinese medicine (TCM) wellness and professional orthopedic services, as well as operates offline examination and polyclinic centers that offers convenient and professional healthcare services. The company offers pharmaceutical and healthcare products through direct sales, and online marketplace and on-demand retail businesses. It serves pharmaceutical and healthcare product companies. JD Health International Inc. was founded in 2014 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Jd Health International Inc reported revenue of 73.4B CNY in FY2025 versus 30.7B CNY in FY2021, a compound +24.4%/yr. Reported net income was 5.4B CNY in FY2025.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$73.4B
Latest YoY
+26.3%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.3%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+30.5%
Avg. revenue growth/yr (8Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+38.1%
Value creation/yr (3Y) ⓘEarnings growth per share (CAGR 3 years) plus dividend yield: value created per share and year.
+61.5% (61.5 + 0.0)
Revenue +24.4%/yr
FY21 30.7B CNY
FY22 46.7B CNY
FY23 53.5B CNY
FY24 58.2B CNY
FY25 73.4B CNY
Net income
FY21 −1.1B CNY
FY22 380M CNY
FY23 2.1B CNY
FY24 4.2B CNY
FY25 5.4B CNY

6618 screens 11% overvalued. Compare with Alibaba Health Information Technology Limited →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jd Health International Inc · Fair Value
HK$33.31 −11%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Jd Health International Inc Fair Value". https://www.fairvalue-calculator.com/stock/6618

Peer Group

Pharmaceutical Retailers · 57 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 72 · Top 25%
Fair Value upside −10% · Above median
Return on equity (TTM) 9% · Above median
Return on assets 3% · Above median
Net margin (TTM) 7% · Top 25%
Operating margin (TTM) 4% · Above median
Revenue growth 28% · Top 25%

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 17.6× · Cheaper than median
P/B 1.81× · Pricier than median
P/S (TTM) 1.48× · Pricier than 75% of peers
P/FCF 1.4× · Pricier than median
EV/EBITDA 19.4× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE20 · sector 20
FUTURE100 · sector 19
PAST37 · sector 15
HEALTH100 · sector 98
DIVIDEND0 · sector 63

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Alibaba Health Information Technology Limited 0241 HK$3.26 HK$2.04 −37%
Yifeng Pharmacy Chain Co 603939 ¥22.90 ¥29.07 +27%
DaShenLin Pharmaceutical Group 603233 ¥18.79 ¥23.86 +27%
MedPlus Health Services Limited MEDPLUS ₹656.80 ₹191.97 −71%
LBX Pharmacy Chain Joint Stock Company 603883 ¥13.44 ¥10.57 −21%
Yixintang Pharmaceutical Group 002727 ¥11.61 ¥9.45 −19%
Anhui Huaren Health Pharmaceutical Co 301408 ¥16.31 ¥10.05 −38%
ShuYu Civilian Pharmacy Corp 301017 ¥13.30 ¥5.91 −56%
Apotea AB APOTEA kr 74.15 kr 46.46 −37%
Luyan Pharma Co 002788 ¥10.96 ¥15.91 +45%

Compare Jd Health International Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Jd Health International Inc (6618) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$33.31 versus a price of HK$37.06, about −10% upside (overvalued).
What is the fair value of 6618?
Our model-based fair value for Jd Health International Inc is HK$33.31 (as of Aug 13, 2026), built from audited fundamentals. The current price: HK$37.06.
What is the quality score of 6618?
Jd Health International Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Jd Health International Inc (6618)?
Jd Health International Inc reported trailing-twelve-month revenue of about HK$73.4B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 6618?
The net profit margin of Jd Health International Inc is about 7.3%, meaning it keeps roughly 7.3% of revenue as net income. Based on the latest reported figures.
Free · no account needed

Watch Jd Health International Inc in the live analysis

One click puts Jd Health International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.